The line-up is revealed to include Merck & Co and J&J itself.
ApexOnco Front Page
Recent articles
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
Innovent’s perseverance with a cytokine approach is rewarded with $1.2bn from Takeda.
But Perspective sinks again.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
